When comparing the performance of FDG-PET versus other CSF and PET biomarkers in regard to their accuracy to detect AD converters, FDG-PET performed better than CSF Aβ1–42 (LR+ 4.0), p-tau (LR+ 3.3), and t-tau (LR+ 2.9) biomarkers individually, but worse than flutemetamol PET (LR+ 4.0). The gene discussed is MAPT; the disease is Alzheimer disease.